Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cellectis S.A. (CLLS : NSDQ)
 
 • Company Description   
Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

Number of Employees: 294

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.78 Daily Weekly Monthly
20 Day Moving Average: 164,287 shares
Shares Outstanding: 45.49 (millions)
Market Capitalization: $171.96 (millions)
Beta: 2.24
52 Week High: $16.67
52 Week Low: $2.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.03% 6.96%
12 Week -11.89% -3.14%
Year To Date -53.45% -40.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8 RUE DE LA CROIX JARRY
-
PARIS,I0 75013
FRA
ph: 33-1-81-69-16-00
fax: 33-1-81-69-16-06
investors@cellectis.com http://www.cellectis.com
 
 • General Corporate Information   
Officers
Andre Choulika - Chief Executive Officer
Jean-Pierre Garnier - Chairman of the Board
Bing Wang - Chief Financial Officer
David Sourdive - Executive Vice President
Laurent Arthaud - Director

Peer Information
Cellectis S.A. (CORR.)
Cellectis S.A. (RSPI)
Cellectis S.A. (CGXP)
Cellectis S.A. (BGEN)
Cellectis S.A. (GTBP)
Cellectis S.A. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 15117K103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 45.49
Most Recent Split Date: (:1)
Beta: 2.24
Market Capitalization: $171.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.85
Price/Cash Flow: -
Price / Sales: 4.00
EPS Growth
vs. Year Ago Period: -150.00%
vs. Previous Quarter: -27.27%
Sales Growth
vs. Year Ago Period: -86.30%
vs. Previous Quarter: -71.95%
ROE
03/31/22 - -53.48
12/31/21 - -41.88
09/30/21 - -44.64
ROA
03/31/22 - -33.57
12/31/21 - -26.94
09/30/21 - -29.13
Current Ratio
03/31/22 - 3.73
12/31/21 - 4.57
09/30/21 - 4.75
Quick Ratio
03/31/22 - 3.73
12/31/21 - 4.57
09/30/21 - 4.72
Operating Margin
03/31/22 - -312.64
12/31/21 - -170.26
09/30/21 - -188.02
Net Margin
03/31/22 - -312.64
12/31/21 - -170.26
09/30/21 - -188.02
Pre-Tax Margin
03/31/22 - -336.58
12/31/21 - -186.53
09/30/21 - -205.18
Book Value
03/31/22 - 4.46
12/31/21 - 5.20
09/30/21 - 5.77
Inventory Turnover
03/31/22 - 22.79
12/31/21 - 13.26
09/30/21 - 17.04
Debt-to-Equity
03/31/22 - 0.09
12/31/21 - 0.08
09/30/21 - 0.09
Debt-to-Capital
03/31/22 - 8.29
12/31/21 - 7.81
09/30/21 - 7.99
 

Powered by Zacks Investment Research ©